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Some evidence would indicate that a serotonergic deficit may be involved in epileptogenesis. A preliminary trial of citalopram,
a selective inhibitor of serotonin reuptake, was carried out. Citalopram 20 mg/day was given to 11 non-depressed patients with
poorly controlled epilepsy as an add on treatment with an open label design for 8–10 months. The median seizure frequency
dropped by 55.6% in the whole group, with nine patients improving by at least 50%. No adverse reactions occurred with the
exception of mild drowsiness. There were no changes of post-treatment as compared to pre-treatment AED serum concentrations.
Although controlled studies are required to confirm the anticonvulsant effect of citalopram, these findings may be regarded as
an indirect evidence of serotonergic impairment in human epileptogenesis.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Some evidence would indicate that a serotoner-
gic deficit may be involved in epileptogenesis.
An antiepileptic effect of 5-hydroxy-tryptophane
(5-HTP), the precursor of serotonin (5-HT), has been
shown in the experimental animal1, and the plasma
level of 5-HTP is lower in epileptics than in controls2.
Furthermore, fluoxetine, a selective inhibitor of sero-
tonin uptake, showed anticonvulsant effect both in
the experimental animal3 and in man4.
Fluoxetine however has also other CNS effects, such
as an inhibition of central nicotinic ACh receptors5 and
a stimulatory effect on allopregnanolone production6,
which might partly account for its antiepileptic action.
Citalopram is more selective than fluoxetine in block-
ing the serotonin reuptake7, and we set out to investi-
gate whether also this agent exerts any anticonvulsant
efficacy in patients with epilepsy.
METHODS AND PATIENTS
Following informed consent, 11 epileptic patients
(nine women and two men, mean age 40.9 years±15.4
SD) with unsatisfactory control of seizures (at least
two seizures per month) entered this study. Demo-
graphic and clinical details of individual patients
are indicated in Table 1. All patients suffered from
cryptogenic complex partial seizures, and some
had secondary generalisation. Two patients were in
monotherapy and nine were in polytherapy. Drug reg-
imen had not been changed for at least 2 months, and
serum concentrations of antiepileptic drugs (AEDs)
were within the therapeutic range. No patient was
clinically depressed (Hamilton Depression Rating
Scale score was lower than 10), or had a family his-
tory of depression. All patients received citalopram
20 mg in a single daily administration as an add-on
therapy for 8–10 months.















Table 1: Summary of demographic and clinical details of patients.
Subject Sex Age Illness duration Seizure type Average monthly seizure frequency Seizure frequency Concomitant AED Plasma levels (mcg/ml) Duration of
(years) reduction (%) treatment (months)
Before After Before After
treatment treatment therapy therapy
1 M 19 2 Secondary generalised 2 0.75 62.5 Carbamazepine 8.1 7.9 8
2 F 60 35 Partial complex 9 4 55.6 Carbamazepine 4.0 3.9 9
3 F 36 20 Generalized and partial
complex
4 2 50 Carbamazepine 4.2 4.5 9
Phenobarbital 14.5 15.1
4 F 37 29 Partial complex 60 3 95 Barbexaclone 18.1a 17.9a 10
Topiramate n.a. n.a.
5 F 41 30 Partial complex 3 0 100 Phenobarbital 19.1 18.3 9
Carbamazepine 6.3 6.0
6 F 29 14 Partial complex 8 4 50 Carbamazepine 5.7 5.8 8
Topiramate n.a. n.a.
Phenobarbital 23.6 22.2
7 M 45 38 Partial complex 60 30 50 Carbamazepine 5.0 5.2 9
Topiramate n.a n.a
8 F 67 27 Secondary generalised 4 3 25 Phenobarbital 24.1 24.2 8
Phenytoin 13.8 14.0
9 F 18 3 Secondary generalised 3 0.6 80 Valproate 60.2 62.2 10
Barbexaclone 28.5a 33.1a
10 F 48 41 Partial complex 60 4 93.3 Phenobarbital 20.1 22.3 9
Carbamazepine 6.4 6.7
11 F 50 10 Partial complex 8 4.5 43.7 Valproate 94.8 92.1 10
Topiramate n.a. n.a
n.a. = not available.
a Assessed as plasma levels of phenobarbital.
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Clinical chemistry and serum concentrations of con-
comitant AEDs were assessed just before starting the
trial and after 1 month of treatment with citalopram.
EEG was recorded before and at least once during the
study.
RESULTS
The results are summarised in Table 1. Baseline
seizure frequency was the average monthly number
of seizures during the 6 months preceding the trial,
and post-treatment seizure frequency was the average
monthly number of seizures while receiving citalo-
pram. Percent changes of post-treatment frequency
with respect to baseline were analysed by descriptive
and non-parametric statistics.
During the treatment with citalopram there was a
mean reduction of seizure frequency by 64.1% (me-
dian reduction = 55.6%). One patient (N. 4) with a
history of daily seizures was almost free from seizures
for the whole treatment period. On the whole, four pa-
tients improved by more than 75%, five patients by at
least 50%, two patients by less than 50%. Nine patients
experienced mild drowsiness in the first 2–3 days of
treatment but no major adverse reactions were re-
ported. No changes of clinical chemistry, AED serum
concentrations and EEG were observed in the course
of treatment.
DISCUSSION
The results indicate that citalopram may be useful
in epileptic patients not only as a treatment for con-
comitant depression, but also for the amelioration of
epilepsy itself. The association between depression
and epilepsy has been known since antiquity, and inter-
ictal depression occurs at some time in up to two-thirds
of patients, especially those with severe and/or fre-
quent seizures8. The importance of treating depressive
illness in patients with epilepsy has been emphasised,
and antidepressants are usually necessary8. However,
the reported incidence of seizures occurring with an-
tidepressants has ranged from 0.1 to 4%9. The higher
incidence is often related to higher antidepressant
dosages in smaller population samples whereas large
scale data sets, for example with imipramine, have
shown an incidence of 0.3–0.6%9. Tricyclic antide-
pressants have the highest epileptogenic effect, but
a proconvulsant effect has also been reported for
trazodone10, 11 and bupropion12. The availability of
drugs effective on depression with no harmful effect
on epilepsy would obviously be of a practical im-
portance. The administration of citalopram as add-on
therapy has replicated the results already obtained
with fluoxetine, by decreasing the seizure frequency
in patients with poorly controlled epilepsy4. This ef-
fect is unlikely to depend on control of depression or
anxiety, because no patient was clinically depressed.
Since citalopram is a more selective inhibitor of sero-
tonin reuptake, this result is a further, though indirect,
evidence of a serotonergic impairment as a possible
mechanism of epilepsy. Although controlled studies
are required to validate this hypothesis, the antiepilep-
tic action of both citalopram and fluoxetine would in-
dicate that an anticonvulsant effect can be obtained not
only by affecting the GABA and glutamate systems13,
but also by potentiating serotonergic activity.
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